164 related articles for article (PubMed ID: 1517688)
1. von Willebrand factor antigen, tissue-type plasminogen activator antigen, and risk of death in human immunodeficiency virus 1-related clinical disease: independent prognostic relevance of tissue-type plasminogen activator.
Schved JF; Gris JC; Arnaud A; Martinez P; Sanchez N; Wautier JL; Sarlat C
J Lab Clin Med; 1992 Sep; 120(3):411-9. PubMed ID: 1517688
[TBL] [Abstract][Full Text] [Related]
2. Altered endothelial function following the Fontan procedure.
Binotto MA; Maeda NY; Lopes AA
Cardiol Young; 2008 Feb; 18(1):70-4. PubMed ID: 18093358
[TBL] [Abstract][Full Text] [Related]
3. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].
Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T; Lecha N; Rubio Rivas C
An Med Interna; 2000 Oct; 17(10):533-7. PubMed ID: 11109648
[TBL] [Abstract][Full Text] [Related]
4. Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism.
Levesque H; Borg JY; Cailleux N; Vasse M; Daliphard S; Gancel A; Monconduit M; Courtois H
Eur J Med; 1993 May; 2(5):287-8. PubMed ID: 8252160
[TBL] [Abstract][Full Text] [Related]
5. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis.
Blann AD; Dobrotova M; Kubisz P; McCollum CN
Thromb Haemost; 1995 Aug; 74(2):626-30. PubMed ID: 8584997
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
[TBL] [Abstract][Full Text] [Related]
7. [Thrombomodulin, von Willebrand factor and tissue plasminogen activator in the blood plasma of obese women and men].
Rość D; Drewniak W; Kinasz-Rózycka I; Kulwas A; Michalski A
Pol Merkur Lekarski; 2003 Dec; 15(90):518-20. PubMed ID: 15058251
[TBL] [Abstract][Full Text] [Related]
8. [Tissue plasminogen activator as a prognostic factor in myocardial infarct patients].
Fernández Abellán P; Marín Ortuño F; Marco Vera P; Luján Martínez J
Rev Clin Esp; 1999 Apr; 199(4):215-7. PubMed ID: 10364793
[TBL] [Abstract][Full Text] [Related]
9. Changes in plasma C-reactive protein and hemostatic factors prior to and after a first myocardial infarction with a median follow-up time of 8 years.
Thøgersen AM; Nilsson TK; Weinehall L; Boman K; Eliasson M; Hallmans G; Jansson JH
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):340-6. PubMed ID: 19357504
[TBL] [Abstract][Full Text] [Related]
10. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
11. Von Willebrand factor, plasminogen activator inhibitor-1 and C-reactive protein are markers of thrombolytic efficacy in acute myocardial infarction.
Andreotti F; Hackett DR; Haider AW; Roncaglioni MC; Davies GJ; Beacham JL; Kluft C; Maseri A
Thromb Haemost; 1992 Dec; 68(6):678-82. PubMed ID: 1287882
[TBL] [Abstract][Full Text] [Related]
12. Fibrinolysis and coagulation in patients with infectious disease and sepsis.
Philippé J; Offner F; Declerck PJ; Leroux-Roels G; Vogelaers D; Baele G; Collen D
Thromb Haemost; 1991 Mar; 65(3):291-5. PubMed ID: 1904655
[TBL] [Abstract][Full Text] [Related]
13. Contribution of platelets to increased plasminogen activator inhibitor type 1 in severe preeclampsia.
Gilabert J; Estellés A; Aznar J; España F; Andrés C; Santos T; Vallés J
Thromb Haemost; 1990 Jun; 63(3):361-6. PubMed ID: 2144918
[TBL] [Abstract][Full Text] [Related]
14. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis.
Huber K; Jörg M; Probst P; Schuster E; Lang I; Kaindl F; Binder BR
Thromb Haemost; 1992 Feb; 67(2):209-13. PubMed ID: 1621240
[TBL] [Abstract][Full Text] [Related]
15. Evidence of endothelial dysfunction in patients with functionally univentricular physiology before completion of the Fontan operation.
Binotto MA; Maeda NY; Lopes AA
Cardiol Young; 2005 Feb; 15(1):26-30. PubMed ID: 15831157
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
[TBL] [Abstract][Full Text] [Related]
18. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
[TBL] [Abstract][Full Text] [Related]
19. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
20. Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, factor VIII:C and in erythrocyte sedimentation rate with age.
Aillaud MF; Pignol F; Alessi MC; Harle JR; Escande M; Mongin M; Juhan-Vague I
Thromb Haemost; 1986 Jun; 55(3):330-2. PubMed ID: 3092390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
